An­oth­er day, an­oth­er ADC: On­Cusp se­cures $100M Se­ries A from No­vo, Or­biMed and oth­ers to run PhI tri­al

The an­ti­body-drug con­ju­gate news keeps flow­ing: On­Cusp Ther­a­peu­tics is the lat­est to join the are­na with an over­sub­scribed $100 mil­lion Se­ries A un­veiled Thurs­day morn­ing.

The start­up, found­ed in 2021, adds to the rush of AD­Cs in re­cent years as the bio­phar­ma in­dus­try races to in­no­vate on the decades-old tech­nol­o­gy, which seeks to cre­ate a fanci­er, more pre­cise and safer ver­sion of chemother­a­py.

And like many of the deals that have been an­nounced in this space in re­cent quar­ters, On­Cusp has roots in both the US and Chi­na, where Big Phar­mas have turned to again and again for pacts with re­gion­al biotechs MediLink, Du­al­i­ty­Bio, Han­soh, Sys­tIm­mune and oth­ers. On­Cusp is based in New York and has an of­fice in Shang­hai, ac­cord­ing to its web­site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER